PSTV Surges 40%: UnitedHealthcare Deal Boosts Cancer Detection Tool

PSTV Surges 40%: UnitedHealthcare Deal Boosts Cancer Detection Tool
Investors are buzzing this morning as Plus Therapeutics (ticker: PSTV) shares have seen an impressive surge, rocketing up a significant 40% in early trading. This notable jump, from yesterday's closing price around $0.40 to approximately $0.57, has captured the attention of both day traders and long-term investors alike, signaling a potentially transformative moment for the small-cap biotech firm. This sudden upward movement underscores the profound impact that strategic partnerships can have on a company's trajectory, particularly within the dynamic biotechnology sector. The Game-Changing News Behind the Rally The catalyst for today's dramatic stock performance is a pivotal announcement from Plus Therapeutics, a Houston-based company dedicated to combating aggressive cancers of the brain and central nervous system. Their diagnostic division, CNSide Diagnostics, has successfully secured a national coverage agreement with UnitedHealthcare. This is no small feat, considering U…